Clinical Trial Update: Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of everolimus (RAD001) plus panobinostat (LBH589) in EBV-driven solid tumors, including nasopharyngeal carcinoma and lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-positive Solid Tumors
• Lymphoma
• Nasopharyngeal Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• Farydak (panobinostat)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour | Phase 1 | Status: UNKNOWN